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TO THE EDITOR: We congratulate Kerr et al1 for a fair and
comprehensive overview of decision curve analysis for evaluating
risk predictionmodels in a clinical context. Althoughwe agree with
the authors on many points, there are three areas in which we feel
further discussion is justiﬁed.
First, the authors imply that models can be placed in one of
two categories—well-calibrated or miscalibrated—and suggest
that it is not appropriate to use decision curves in the presence of
miscalibration. Our view is that all models are miscalibrated to
some extent when applied in a new setting. Decision curves are
a useful tool for determining whether the degree, direction, and
range of miscalibration are clinically important.2 It is easily shown
that some types of miscalibration matter more than others. For
instance, a model might substantially overestimate risk of cancer
recurrence in a subgroup of patients already considered high risk.
But there are no clinical implications of this type of miscalibration,
because all patients in the high-risk subgroup would receive ad-
juvant treatment, irrespective of whether their risk is considered
very high or extremely high. As a second example, a model might
slightly underestimate the risk of cancer in patients participat-
ing in an early detection program. Although the degree of un-
derestimation is only slight, the consequences are so important—a
higher risk of missing cancer—that this might dictate that the
model should not be used in clinical practice. Kerr et al might call
both models “miscalibrated” and recommend against the use of
decision curves on the grounds that “one should not use [decision
curves] with a miscalibrated model.”1(p2537) On the contrary,
decision curves would help determine whether miscalibration
was clinically relevant.
The authors make an interesting conceptual advance in
pointing out that net beneﬁt can vary by subpopulation. But they
then make a relatively strong claim in stating that decision curves
are “valid only if the distribution of predicted risks among cases
and controls in each subpopulation is the same as in the whole
population, and the prevalence of [the undesireable outcome] is
constant across subpopulations.”1(p2538) This claim holds only
under certain circumstances. For instance, if older patients have
both higher risk thresholds and higher prevalence, then marginal
net beneﬁt will be quite similar for older and younger patients. The
key point is that the need to calculate decision curves separately for
subpopulations must be demonstrated empirically on the basis
of real data and subpopulations. Clinical trials provide a suitable
analogy. It may well be that different subpopulations respond
differently to a drug and that we should calculate effect sizes
separately in subpopulations. But we start by basing decisions on
the overall effect size for the clinical trial population and move to
subgroups only if there is compelling evidence of heterogeneity in
the treatment effects.
Finally, we are delighted that the authors have developed an R
package to run decision curves. Readers might like to know that
software for SAS and Stata, along with tutorials and data sets, is
available at http://www.decisioncurveanalysis.org.
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